nodes	percent_of_prediction	percent_of_DWPC	metapath
Cevimeline—FMO1—Tamoxifen—pancreatic cancer	0.611	0.841	CbGbCtD
Cevimeline—CYP2D6—Tamoxifen—pancreatic cancer	0.0235	0.0324	CbGbCtD
Cevimeline—CYP2D6—Erlotinib—pancreatic cancer	0.02	0.0275	CbGbCtD
Cevimeline—CYP3A4—Tamoxifen—pancreatic cancer	0.015	0.0206	CbGbCtD
Cevimeline—CYP3A4—Erlotinib—pancreatic cancer	0.0127	0.0175	CbGbCtD
Cevimeline—CYP3A4—Irinotecan—pancreatic cancer	0.0115	0.0158	CbGbCtD
Cevimeline—CYP2D6—Doxorubicin—pancreatic cancer	0.00987	0.0136	CbGbCtD
Cevimeline—CYP3A4—Docetaxel—pancreatic cancer	0.00842	0.0116	CbGbCtD
Cevimeline—CYP3A4—Sunitinib—pancreatic cancer	0.00838	0.0115	CbGbCtD
Cevimeline—CYP3A4—Doxorubicin—pancreatic cancer	0.00628	0.00864	CbGbCtD
Cevimeline—Body temperature increased—Fluorouracil—pancreatic cancer	9.11e-05	0.000356	CcSEcCtD
Cevimeline—Eosinophilia—Doxorubicin—pancreatic cancer	9.03e-05	0.000353	CcSEcCtD
Cevimeline—Palpitations—Docetaxel—pancreatic cancer	9e-05	0.000352	CcSEcCtD
Cevimeline—Photosensitivity reaction—Epirubicin—pancreatic cancer	9e-05	0.000352	CcSEcCtD
Cevimeline—Weight increased—Epirubicin—pancreatic cancer	8.97e-05	0.000351	CcSEcCtD
Cevimeline—Loss of consciousness—Docetaxel—pancreatic cancer	8.95e-05	0.00035	CcSEcCtD
Cevimeline—Weight decreased—Epirubicin—pancreatic cancer	8.92e-05	0.000349	CcSEcCtD
Cevimeline—Hyperglycaemia—Epirubicin—pancreatic cancer	8.9e-05	0.000348	CcSEcCtD
Cevimeline—Cough—Docetaxel—pancreatic cancer	8.89e-05	0.000347	CcSEcCtD
Cevimeline—Angina pectoris—Doxorubicin—pancreatic cancer	8.89e-05	0.000347	CcSEcCtD
Cevimeline—Hypersensitivity—Irinotecan—pancreatic cancer	8.86e-05	0.000346	CcSEcCtD
Cevimeline—Pneumonia—Epirubicin—pancreatic cancer	8.84e-05	0.000345	CcSEcCtD
Cevimeline—Convulsion—Docetaxel—pancreatic cancer	8.83e-05	0.000345	CcSEcCtD
Cevimeline—Hypertension—Docetaxel—pancreatic cancer	8.79e-05	0.000344	CcSEcCtD
Cevimeline—Bronchitis—Doxorubicin—pancreatic cancer	8.77e-05	0.000343	CcSEcCtD
Cevimeline—Myalgia—Docetaxel—pancreatic cancer	8.67e-05	0.000339	CcSEcCtD
Cevimeline—Chest pain—Docetaxel—pancreatic cancer	8.67e-05	0.000339	CcSEcCtD
Cevimeline—Arthralgia—Docetaxel—pancreatic cancer	8.67e-05	0.000339	CcSEcCtD
Cevimeline—Nausea—Sunitinib—pancreatic cancer	8.67e-05	0.000339	CcSEcCtD
Cevimeline—Asthenia—Irinotecan—pancreatic cancer	8.63e-05	0.000337	CcSEcCtD
Cevimeline—Neuropathy peripheral—Epirubicin—pancreatic cancer	8.62e-05	0.000337	CcSEcCtD
Cevimeline—Stomatitis—Epirubicin—pancreatic cancer	8.57e-05	0.000335	CcSEcCtD
Cevimeline—Conjunctivitis—Epirubicin—pancreatic cancer	8.55e-05	0.000334	CcSEcCtD
Cevimeline—Urinary tract infection—Epirubicin—pancreatic cancer	8.55e-05	0.000334	CcSEcCtD
Cevimeline—Dysuria—Doxorubicin—pancreatic cancer	8.53e-05	0.000333	CcSEcCtD
Cevimeline—Hypersensitivity—Fluorouracil—pancreatic cancer	8.49e-05	0.000332	CcSEcCtD
Cevimeline—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	8.48e-05	0.000331	CcSEcCtD
Cevimeline—Pollakiuria—Doxorubicin—pancreatic cancer	8.43e-05	0.000329	CcSEcCtD
Cevimeline—Asthenia—Gemcitabine—pancreatic cancer	8.41e-05	0.000328	CcSEcCtD
Cevimeline—Haematuria—Epirubicin—pancreatic cancer	8.38e-05	0.000328	CcSEcCtD
Cevimeline—Confusional state—Docetaxel—pancreatic cancer	8.38e-05	0.000327	CcSEcCtD
Cevimeline—Photosensitivity reaction—Doxorubicin—pancreatic cancer	8.33e-05	0.000325	CcSEcCtD
Cevimeline—Oedema—Docetaxel—pancreatic cancer	8.31e-05	0.000325	CcSEcCtD
Cevimeline—Weight increased—Doxorubicin—pancreatic cancer	8.3e-05	0.000324	CcSEcCtD
Cevimeline—Epistaxis—Epirubicin—pancreatic cancer	8.29e-05	0.000324	CcSEcCtD
Cevimeline—Pruritus—Gemcitabine—pancreatic cancer	8.29e-05	0.000324	CcSEcCtD
Cevimeline—Infection—Docetaxel—pancreatic cancer	8.26e-05	0.000323	CcSEcCtD
Cevimeline—Weight decreased—Doxorubicin—pancreatic cancer	8.25e-05	0.000322	CcSEcCtD
Cevimeline—Sinusitis—Epirubicin—pancreatic cancer	8.25e-05	0.000322	CcSEcCtD
Cevimeline—Hyperglycaemia—Doxorubicin—pancreatic cancer	8.23e-05	0.000322	CcSEcCtD
Cevimeline—Diarrhoea—Irinotecan—pancreatic cancer	8.23e-05	0.000321	CcSEcCtD
Cevimeline—Agranulocytosis—Epirubicin—pancreatic cancer	8.21e-05	0.000321	CcSEcCtD
Cevimeline—Pneumonia—Doxorubicin—pancreatic cancer	8.18e-05	0.00032	CcSEcCtD
Cevimeline—Shock—Docetaxel—pancreatic cancer	8.18e-05	0.00032	CcSEcCtD
Cevimeline—Nervous system disorder—Docetaxel—pancreatic cancer	8.15e-05	0.000319	CcSEcCtD
Cevimeline—Pruritus—Fluorouracil—pancreatic cancer	8.15e-05	0.000318	CcSEcCtD
Cevimeline—Thrombocytopenia—Docetaxel—pancreatic cancer	8.14e-05	0.000318	CcSEcCtD
Cevimeline—Tachycardia—Docetaxel—pancreatic cancer	8.11e-05	0.000317	CcSEcCtD
Cevimeline—Skin disorder—Docetaxel—pancreatic cancer	8.08e-05	0.000315	CcSEcCtD
Cevimeline—Diarrhoea—Gemcitabine—pancreatic cancer	8.02e-05	0.000313	CcSEcCtD
Cevimeline—Neuropathy peripheral—Doxorubicin—pancreatic cancer	7.97e-05	0.000312	CcSEcCtD
Cevimeline—Dizziness—Irinotecan—pancreatic cancer	7.95e-05	0.000311	CcSEcCtD
Cevimeline—Haemoglobin—Epirubicin—pancreatic cancer	7.93e-05	0.00031	CcSEcCtD
Cevimeline—Stomatitis—Doxorubicin—pancreatic cancer	7.93e-05	0.00031	CcSEcCtD
Cevimeline—Anorexia—Docetaxel—pancreatic cancer	7.92e-05	0.00031	CcSEcCtD
Cevimeline—Rhinitis—Epirubicin—pancreatic cancer	7.91e-05	0.000309	CcSEcCtD
Cevimeline—Conjunctivitis—Doxorubicin—pancreatic cancer	7.91e-05	0.000309	CcSEcCtD
Cevimeline—Urinary tract infection—Doxorubicin—pancreatic cancer	7.91e-05	0.000309	CcSEcCtD
Cevimeline—Haemorrhage—Epirubicin—pancreatic cancer	7.89e-05	0.000308	CcSEcCtD
Cevimeline—Diarrhoea—Fluorouracil—pancreatic cancer	7.88e-05	0.000308	CcSEcCtD
Cevimeline—Hypoaesthesia—Epirubicin—pancreatic cancer	7.85e-05	0.000307	CcSEcCtD
Cevimeline—Pharyngitis—Epirubicin—pancreatic cancer	7.83e-05	0.000306	CcSEcCtD
Cevimeline—Oedema peripheral—Epirubicin—pancreatic cancer	7.78e-05	0.000304	CcSEcCtD
Cevimeline—Hypotension—Docetaxel—pancreatic cancer	7.77e-05	0.000303	CcSEcCtD
Cevimeline—Haematuria—Doxorubicin—pancreatic cancer	7.76e-05	0.000303	CcSEcCtD
Cevimeline—Urethral disorder—Epirubicin—pancreatic cancer	7.74e-05	0.000302	CcSEcCtD
Cevimeline—Epistaxis—Doxorubicin—pancreatic cancer	7.67e-05	0.0003	CcSEcCtD
Cevimeline—Vomiting—Irinotecan—pancreatic cancer	7.65e-05	0.000299	CcSEcCtD
Cevimeline—Sinusitis—Doxorubicin—pancreatic cancer	7.63e-05	0.000298	CcSEcCtD
Cevimeline—Dizziness—Fluorouracil—pancreatic cancer	7.62e-05	0.000298	CcSEcCtD
Cevimeline—Visual impairment—Epirubicin—pancreatic cancer	7.61e-05	0.000297	CcSEcCtD
Cevimeline—Agranulocytosis—Doxorubicin—pancreatic cancer	7.59e-05	0.000297	CcSEcCtD
Cevimeline—Rash—Irinotecan—pancreatic cancer	7.58e-05	0.000296	CcSEcCtD
Cevimeline—Dermatitis—Irinotecan—pancreatic cancer	7.58e-05	0.000296	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	7.57e-05	0.000296	CcSEcCtD
Cevimeline—Headache—Irinotecan—pancreatic cancer	7.53e-05	0.000294	CcSEcCtD
Cevimeline—Insomnia—Docetaxel—pancreatic cancer	7.52e-05	0.000294	CcSEcCtD
Cevimeline—Paraesthesia—Docetaxel—pancreatic cancer	7.47e-05	0.000292	CcSEcCtD
Cevimeline—Vomiting—Gemcitabine—pancreatic cancer	7.45e-05	0.000291	CcSEcCtD
Cevimeline—Dyspnoea—Docetaxel—pancreatic cancer	7.41e-05	0.00029	CcSEcCtD
Cevimeline—Somnolence—Docetaxel—pancreatic cancer	7.39e-05	0.000289	CcSEcCtD
Cevimeline—Rash—Gemcitabine—pancreatic cancer	7.39e-05	0.000289	CcSEcCtD
Cevimeline—Dermatitis—Gemcitabine—pancreatic cancer	7.38e-05	0.000288	CcSEcCtD
Cevimeline—Eye disorder—Epirubicin—pancreatic cancer	7.38e-05	0.000288	CcSEcCtD
Cevimeline—Tinnitus—Epirubicin—pancreatic cancer	7.36e-05	0.000287	CcSEcCtD
Cevimeline—Haemoglobin—Doxorubicin—pancreatic cancer	7.34e-05	0.000287	CcSEcCtD
Cevimeline—Headache—Gemcitabine—pancreatic cancer	7.34e-05	0.000287	CcSEcCtD
Cevimeline—Cardiac disorder—Epirubicin—pancreatic cancer	7.33e-05	0.000286	CcSEcCtD
Cevimeline—Flushing—Epirubicin—pancreatic cancer	7.33e-05	0.000286	CcSEcCtD
Cevimeline—Vomiting—Fluorouracil—pancreatic cancer	7.32e-05	0.000286	CcSEcCtD
Cevimeline—Rhinitis—Doxorubicin—pancreatic cancer	7.32e-05	0.000286	CcSEcCtD
Cevimeline—Dyspepsia—Docetaxel—pancreatic cancer	7.32e-05	0.000286	CcSEcCtD
Cevimeline—Haemorrhage—Doxorubicin—pancreatic cancer	7.3e-05	0.000285	CcSEcCtD
Cevimeline—Hypoaesthesia—Doxorubicin—pancreatic cancer	7.27e-05	0.000284	CcSEcCtD
Cevimeline—Rash—Fluorouracil—pancreatic cancer	7.26e-05	0.000284	CcSEcCtD
Cevimeline—Dermatitis—Fluorouracil—pancreatic cancer	7.26e-05	0.000283	CcSEcCtD
Cevimeline—Pharyngitis—Doxorubicin—pancreatic cancer	7.25e-05	0.000283	CcSEcCtD
Cevimeline—Decreased appetite—Docetaxel—pancreatic cancer	7.23e-05	0.000282	CcSEcCtD
Cevimeline—Headache—Fluorouracil—pancreatic cancer	7.22e-05	0.000282	CcSEcCtD
Cevimeline—Oedema peripheral—Doxorubicin—pancreatic cancer	7.19e-05	0.000281	CcSEcCtD
Cevimeline—Fatigue—Docetaxel—pancreatic cancer	7.17e-05	0.00028	CcSEcCtD
Cevimeline—Angiopathy—Epirubicin—pancreatic cancer	7.16e-05	0.00028	CcSEcCtD
Cevimeline—Urethral disorder—Doxorubicin—pancreatic cancer	7.16e-05	0.00028	CcSEcCtD
Cevimeline—Nausea—Irinotecan—pancreatic cancer	7.14e-05	0.000279	CcSEcCtD
Cevimeline—Pain—Docetaxel—pancreatic cancer	7.11e-05	0.000278	CcSEcCtD
Cevimeline—Constipation—Docetaxel—pancreatic cancer	7.11e-05	0.000278	CcSEcCtD
Cevimeline—Chills—Epirubicin—pancreatic cancer	7.08e-05	0.000277	CcSEcCtD
Cevimeline—Arrhythmia—Epirubicin—pancreatic cancer	7.05e-05	0.000275	CcSEcCtD
Cevimeline—Visual impairment—Doxorubicin—pancreatic cancer	7.04e-05	0.000275	CcSEcCtD
Cevimeline—Alopecia—Epirubicin—pancreatic cancer	6.97e-05	0.000272	CcSEcCtD
Cevimeline—Nausea—Gemcitabine—pancreatic cancer	6.96e-05	0.000272	CcSEcCtD
Cevimeline—Malnutrition—Epirubicin—pancreatic cancer	6.87e-05	0.000268	CcSEcCtD
Cevimeline—Feeling abnormal—Docetaxel—pancreatic cancer	6.85e-05	0.000268	CcSEcCtD
Cevimeline—Nausea—Fluorouracil—pancreatic cancer	6.84e-05	0.000267	CcSEcCtD
Cevimeline—Eye disorder—Doxorubicin—pancreatic cancer	6.82e-05	0.000267	CcSEcCtD
Cevimeline—Tinnitus—Doxorubicin—pancreatic cancer	6.81e-05	0.000266	CcSEcCtD
Cevimeline—Gastrointestinal pain—Docetaxel—pancreatic cancer	6.8e-05	0.000266	CcSEcCtD
Cevimeline—Cardiac disorder—Doxorubicin—pancreatic cancer	6.78e-05	0.000265	CcSEcCtD
Cevimeline—Flushing—Doxorubicin—pancreatic cancer	6.78e-05	0.000265	CcSEcCtD
Cevimeline—Flatulence—Epirubicin—pancreatic cancer	6.77e-05	0.000264	CcSEcCtD
Cevimeline—Dysgeusia—Epirubicin—pancreatic cancer	6.73e-05	0.000263	CcSEcCtD
Cevimeline—Back pain—Epirubicin—pancreatic cancer	6.65e-05	0.00026	CcSEcCtD
Cevimeline—Angiopathy—Doxorubicin—pancreatic cancer	6.63e-05	0.000259	CcSEcCtD
Cevimeline—Muscle spasms—Epirubicin—pancreatic cancer	6.61e-05	0.000258	CcSEcCtD
Cevimeline—Abdominal pain—Docetaxel—pancreatic cancer	6.57e-05	0.000257	CcSEcCtD
Cevimeline—Body temperature increased—Docetaxel—pancreatic cancer	6.57e-05	0.000257	CcSEcCtD
Cevimeline—Chills—Doxorubicin—pancreatic cancer	6.55e-05	0.000256	CcSEcCtD
Cevimeline—Arrhythmia—Doxorubicin—pancreatic cancer	6.52e-05	0.000255	CcSEcCtD
Cevimeline—Alopecia—Doxorubicin—pancreatic cancer	6.45e-05	0.000252	CcSEcCtD
Cevimeline—Ill-defined disorder—Epirubicin—pancreatic cancer	6.38e-05	0.000249	CcSEcCtD
Cevimeline—Malnutrition—Doxorubicin—pancreatic cancer	6.36e-05	0.000248	CcSEcCtD
Cevimeline—Anaemia—Epirubicin—pancreatic cancer	6.35e-05	0.000248	CcSEcCtD
Cevimeline—Agitation—Epirubicin—pancreatic cancer	6.31e-05	0.000247	CcSEcCtD
Cevimeline—Flatulence—Doxorubicin—pancreatic cancer	6.26e-05	0.000245	CcSEcCtD
Cevimeline—Dysgeusia—Doxorubicin—pancreatic cancer	6.23e-05	0.000243	CcSEcCtD
Cevimeline—Malaise—Epirubicin—pancreatic cancer	6.2e-05	0.000242	CcSEcCtD
Cevimeline—Vertigo—Epirubicin—pancreatic cancer	6.17e-05	0.000241	CcSEcCtD
Cevimeline—Syncope—Epirubicin—pancreatic cancer	6.16e-05	0.000241	CcSEcCtD
Cevimeline—Leukopenia—Epirubicin—pancreatic cancer	6.15e-05	0.00024	CcSEcCtD
Cevimeline—Back pain—Doxorubicin—pancreatic cancer	6.15e-05	0.00024	CcSEcCtD
Cevimeline—Hypersensitivity—Docetaxel—pancreatic cancer	6.13e-05	0.000239	CcSEcCtD
Cevimeline—Muscle spasms—Doxorubicin—pancreatic cancer	6.11e-05	0.000239	CcSEcCtD
Cevimeline—Palpitations—Epirubicin—pancreatic cancer	6.07e-05	0.000237	CcSEcCtD
Cevimeline—Loss of consciousness—Epirubicin—pancreatic cancer	6.04e-05	0.000236	CcSEcCtD
Cevimeline—Cough—Epirubicin—pancreatic cancer	6e-05	0.000234	CcSEcCtD
Cevimeline—Asthenia—Docetaxel—pancreatic cancer	5.96e-05	0.000233	CcSEcCtD
Cevimeline—Convulsion—Epirubicin—pancreatic cancer	5.95e-05	0.000233	CcSEcCtD
Cevimeline—Hypertension—Epirubicin—pancreatic cancer	5.93e-05	0.000232	CcSEcCtD
Cevimeline—Ill-defined disorder—Doxorubicin—pancreatic cancer	5.9e-05	0.00023	CcSEcCtD
Cevimeline—Pruritus—Docetaxel—pancreatic cancer	5.88e-05	0.00023	CcSEcCtD
Cevimeline—Anaemia—Doxorubicin—pancreatic cancer	5.88e-05	0.00023	CcSEcCtD
Cevimeline—Myalgia—Epirubicin—pancreatic cancer	5.85e-05	0.000229	CcSEcCtD
Cevimeline—Arthralgia—Epirubicin—pancreatic cancer	5.85e-05	0.000229	CcSEcCtD
Cevimeline—Chest pain—Epirubicin—pancreatic cancer	5.85e-05	0.000229	CcSEcCtD
Cevimeline—Agitation—Doxorubicin—pancreatic cancer	5.84e-05	0.000228	CcSEcCtD
Cevimeline—Anxiety—Epirubicin—pancreatic cancer	5.83e-05	0.000228	CcSEcCtD
Cevimeline—Discomfort—Epirubicin—pancreatic cancer	5.78e-05	0.000226	CcSEcCtD
Cevimeline—Malaise—Doxorubicin—pancreatic cancer	5.73e-05	0.000224	CcSEcCtD
Cevimeline—Vertigo—Doxorubicin—pancreatic cancer	5.71e-05	0.000223	CcSEcCtD
Cevimeline—Syncope—Doxorubicin—pancreatic cancer	5.7e-05	0.000223	CcSEcCtD
Cevimeline—Leukopenia—Doxorubicin—pancreatic cancer	5.69e-05	0.000222	CcSEcCtD
Cevimeline—Diarrhoea—Docetaxel—pancreatic cancer	5.69e-05	0.000222	CcSEcCtD
Cevimeline—Confusional state—Epirubicin—pancreatic cancer	5.65e-05	0.000221	CcSEcCtD
Cevimeline—Palpitations—Doxorubicin—pancreatic cancer	5.62e-05	0.000219	CcSEcCtD
Cevimeline—Oedema—Epirubicin—pancreatic cancer	5.61e-05	0.000219	CcSEcCtD
Cevimeline—Loss of consciousness—Doxorubicin—pancreatic cancer	5.59e-05	0.000218	CcSEcCtD
Cevimeline—Infection—Epirubicin—pancreatic cancer	5.57e-05	0.000218	CcSEcCtD
Cevimeline—Cough—Doxorubicin—pancreatic cancer	5.55e-05	0.000217	CcSEcCtD
Cevimeline—Shock—Epirubicin—pancreatic cancer	5.52e-05	0.000216	CcSEcCtD
Cevimeline—Convulsion—Doxorubicin—pancreatic cancer	5.51e-05	0.000215	CcSEcCtD
Cevimeline—Nervous system disorder—Epirubicin—pancreatic cancer	5.5e-05	0.000215	CcSEcCtD
Cevimeline—Dizziness—Docetaxel—pancreatic cancer	5.5e-05	0.000215	CcSEcCtD
Cevimeline—Thrombocytopenia—Epirubicin—pancreatic cancer	5.49e-05	0.000214	CcSEcCtD
Cevimeline—Hypertension—Doxorubicin—pancreatic cancer	5.49e-05	0.000214	CcSEcCtD
Cevimeline—Tachycardia—Epirubicin—pancreatic cancer	5.47e-05	0.000214	CcSEcCtD
Cevimeline—Skin disorder—Epirubicin—pancreatic cancer	5.45e-05	0.000213	CcSEcCtD
Cevimeline—Hyperhidrosis—Epirubicin—pancreatic cancer	5.42e-05	0.000212	CcSEcCtD
Cevimeline—Arthralgia—Doxorubicin—pancreatic cancer	5.41e-05	0.000211	CcSEcCtD
Cevimeline—Myalgia—Doxorubicin—pancreatic cancer	5.41e-05	0.000211	CcSEcCtD
Cevimeline—Chest pain—Doxorubicin—pancreatic cancer	5.41e-05	0.000211	CcSEcCtD
Cevimeline—Anxiety—Doxorubicin—pancreatic cancer	5.39e-05	0.000211	CcSEcCtD
Cevimeline—Discomfort—Doxorubicin—pancreatic cancer	5.35e-05	0.000209	CcSEcCtD
Cevimeline—Anorexia—Epirubicin—pancreatic cancer	5.35e-05	0.000209	CcSEcCtD
Cevimeline—Vomiting—Docetaxel—pancreatic cancer	5.29e-05	0.000207	CcSEcCtD
Cevimeline—Rash—Docetaxel—pancreatic cancer	5.24e-05	0.000205	CcSEcCtD
Cevimeline—Hypotension—Epirubicin—pancreatic cancer	5.24e-05	0.000205	CcSEcCtD
Cevimeline—Dermatitis—Docetaxel—pancreatic cancer	5.24e-05	0.000205	CcSEcCtD
Cevimeline—Confusional state—Doxorubicin—pancreatic cancer	5.23e-05	0.000204	CcSEcCtD
Cevimeline—Headache—Docetaxel—pancreatic cancer	5.21e-05	0.000203	CcSEcCtD
Cevimeline—Oedema—Doxorubicin—pancreatic cancer	5.19e-05	0.000203	CcSEcCtD
Cevimeline—Infection—Doxorubicin—pancreatic cancer	5.15e-05	0.000201	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	5.11e-05	0.0002	CcSEcCtD
Cevimeline—Shock—Doxorubicin—pancreatic cancer	5.1e-05	0.000199	CcSEcCtD
Cevimeline—Nervous system disorder—Doxorubicin—pancreatic cancer	5.09e-05	0.000199	CcSEcCtD
Cevimeline—Thrombocytopenia—Doxorubicin—pancreatic cancer	5.08e-05	0.000198	CcSEcCtD
Cevimeline—Insomnia—Epirubicin—pancreatic cancer	5.07e-05	0.000198	CcSEcCtD
Cevimeline—Tachycardia—Doxorubicin—pancreatic cancer	5.06e-05	0.000198	CcSEcCtD
Cevimeline—Skin disorder—Doxorubicin—pancreatic cancer	5.04e-05	0.000197	CcSEcCtD
Cevimeline—Paraesthesia—Epirubicin—pancreatic cancer	5.04e-05	0.000197	CcSEcCtD
Cevimeline—Hyperhidrosis—Doxorubicin—pancreatic cancer	5.02e-05	0.000196	CcSEcCtD
Cevimeline—Dyspnoea—Epirubicin—pancreatic cancer	5e-05	0.000195	CcSEcCtD
Cevimeline—Somnolence—Epirubicin—pancreatic cancer	4.99e-05	0.000195	CcSEcCtD
Cevimeline—Anorexia—Doxorubicin—pancreatic cancer	4.95e-05	0.000193	CcSEcCtD
Cevimeline—Nausea—Docetaxel—pancreatic cancer	4.94e-05	0.000193	CcSEcCtD
Cevimeline—Dyspepsia—Epirubicin—pancreatic cancer	4.94e-05	0.000193	CcSEcCtD
Cevimeline—Decreased appetite—Epirubicin—pancreatic cancer	4.87e-05	0.00019	CcSEcCtD
Cevimeline—Hypotension—Doxorubicin—pancreatic cancer	4.85e-05	0.000189	CcSEcCtD
Cevimeline—Fatigue—Epirubicin—pancreatic cancer	4.83e-05	0.000189	CcSEcCtD
Cevimeline—Constipation—Epirubicin—pancreatic cancer	4.8e-05	0.000187	CcSEcCtD
Cevimeline—Pain—Epirubicin—pancreatic cancer	4.8e-05	0.000187	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	4.73e-05	0.000185	CcSEcCtD
Cevimeline—Insomnia—Doxorubicin—pancreatic cancer	4.69e-05	0.000183	CcSEcCtD
Cevimeline—Paraesthesia—Doxorubicin—pancreatic cancer	4.66e-05	0.000182	CcSEcCtD
Cevimeline—Dyspnoea—Doxorubicin—pancreatic cancer	4.63e-05	0.000181	CcSEcCtD
Cevimeline—Feeling abnormal—Epirubicin—pancreatic cancer	4.62e-05	0.000181	CcSEcCtD
Cevimeline—Somnolence—Doxorubicin—pancreatic cancer	4.61e-05	0.00018	CcSEcCtD
Cevimeline—Gastrointestinal pain—Epirubicin—pancreatic cancer	4.59e-05	0.000179	CcSEcCtD
Cevimeline—Dyspepsia—Doxorubicin—pancreatic cancer	4.57e-05	0.000178	CcSEcCtD
Cevimeline—Decreased appetite—Doxorubicin—pancreatic cancer	4.51e-05	0.000176	CcSEcCtD
Cevimeline—Fatigue—Doxorubicin—pancreatic cancer	4.47e-05	0.000175	CcSEcCtD
Cevimeline—Urticaria—Epirubicin—pancreatic cancer	4.45e-05	0.000174	CcSEcCtD
Cevimeline—Pain—Doxorubicin—pancreatic cancer	4.44e-05	0.000173	CcSEcCtD
Cevimeline—Constipation—Doxorubicin—pancreatic cancer	4.44e-05	0.000173	CcSEcCtD
Cevimeline—Body temperature increased—Epirubicin—pancreatic cancer	4.43e-05	0.000173	CcSEcCtD
Cevimeline—Abdominal pain—Epirubicin—pancreatic cancer	4.43e-05	0.000173	CcSEcCtD
Cevimeline—Feeling abnormal—Doxorubicin—pancreatic cancer	4.28e-05	0.000167	CcSEcCtD
Cevimeline—Gastrointestinal pain—Doxorubicin—pancreatic cancer	4.24e-05	0.000166	CcSEcCtD
Cevimeline—Hypersensitivity—Epirubicin—pancreatic cancer	4.13e-05	0.000161	CcSEcCtD
Cevimeline—Urticaria—Doxorubicin—pancreatic cancer	4.12e-05	0.000161	CcSEcCtD
Cevimeline—Abdominal pain—Doxorubicin—pancreatic cancer	4.1e-05	0.00016	CcSEcCtD
Cevimeline—Body temperature increased—Doxorubicin—pancreatic cancer	4.1e-05	0.00016	CcSEcCtD
Cevimeline—Asthenia—Epirubicin—pancreatic cancer	4.02e-05	0.000157	CcSEcCtD
Cevimeline—Pruritus—Epirubicin—pancreatic cancer	3.97e-05	0.000155	CcSEcCtD
Cevimeline—Diarrhoea—Epirubicin—pancreatic cancer	3.84e-05	0.00015	CcSEcCtD
Cevimeline—Hypersensitivity—Doxorubicin—pancreatic cancer	3.82e-05	0.000149	CcSEcCtD
Cevimeline—Asthenia—Doxorubicin—pancreatic cancer	3.72e-05	0.000145	CcSEcCtD
Cevimeline—Dizziness—Epirubicin—pancreatic cancer	3.71e-05	0.000145	CcSEcCtD
Cevimeline—Pruritus—Doxorubicin—pancreatic cancer	3.67e-05	0.000143	CcSEcCtD
Cevimeline—Vomiting—Epirubicin—pancreatic cancer	3.57e-05	0.000139	CcSEcCtD
Cevimeline—Diarrhoea—Doxorubicin—pancreatic cancer	3.55e-05	0.000139	CcSEcCtD
Cevimeline—Rash—Epirubicin—pancreatic cancer	3.54e-05	0.000138	CcSEcCtD
Cevimeline—Dermatitis—Epirubicin—pancreatic cancer	3.53e-05	0.000138	CcSEcCtD
Cevimeline—Headache—Epirubicin—pancreatic cancer	3.51e-05	0.000137	CcSEcCtD
Cevimeline—Dizziness—Doxorubicin—pancreatic cancer	3.43e-05	0.000134	CcSEcCtD
Cevimeline—Nausea—Epirubicin—pancreatic cancer	3.33e-05	0.00013	CcSEcCtD
Cevimeline—Vomiting—Doxorubicin—pancreatic cancer	3.3e-05	0.000129	CcSEcCtD
Cevimeline—Rash—Doxorubicin—pancreatic cancer	3.27e-05	0.000128	CcSEcCtD
Cevimeline—Dermatitis—Doxorubicin—pancreatic cancer	3.27e-05	0.000128	CcSEcCtD
Cevimeline—Headache—Doxorubicin—pancreatic cancer	3.25e-05	0.000127	CcSEcCtD
Cevimeline—Nausea—Doxorubicin—pancreatic cancer	3.08e-05	0.00012	CcSEcCtD
Cevimeline—CHRM3—Signaling Pathways—SSTR3—pancreatic cancer	1.86e-05	0.00105	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—DTX1—pancreatic cancer	1.86e-05	0.00105	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—SST—pancreatic cancer	1.83e-05	0.00104	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—SST—pancreatic cancer	1.82e-05	0.00103	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PTHLH—pancreatic cancer	1.81e-05	0.00103	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PTCH1—pancreatic cancer	1.81e-05	0.00103	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PTHLH—pancreatic cancer	1.81e-05	0.00103	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PTCH1—pancreatic cancer	1.81e-05	0.00103	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—pancreatic cancer	1.79e-05	0.00102	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—SSTR1—pancreatic cancer	1.79e-05	0.00101	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—pancreatic cancer	1.79e-05	0.00101	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—SSTR1—pancreatic cancer	1.78e-05	0.00101	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PPY—pancreatic cancer	1.76e-05	0.000995	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PPY—pancreatic cancer	1.75e-05	0.000991	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—SSTR2—pancreatic cancer	1.72e-05	0.000976	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—SSTR2—pancreatic cancer	1.72e-05	0.000973	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—CNR1—pancreatic cancer	1.69e-05	0.000956	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—CNR1—pancreatic cancer	1.68e-05	0.000953	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CCKBR—pancreatic cancer	1.66e-05	0.000943	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—SST—pancreatic cancer	1.66e-05	0.000941	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CCKBR—pancreatic cancer	1.66e-05	0.00094	CbGpPWpGaD
Cevimeline—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	1.65e-05	0.000938	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—SST—pancreatic cancer	1.65e-05	0.000938	CbGpPWpGaD
Cevimeline—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	1.65e-05	0.000935	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—PTEN—pancreatic cancer	1.65e-05	0.000933	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pancreatic cancer	1.63e-05	0.000926	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—GCG—pancreatic cancer	1.63e-05	0.000923	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pancreatic cancer	1.63e-05	0.000923	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—GCG—pancreatic cancer	1.62e-05	0.00092	CbGpPWpGaD
Cevimeline—CHRM1—G alpha (q) signalling events—PIK3CA—pancreatic cancer	1.59e-05	0.000898	CbGpPWpGaD
Cevimeline—CHRM3—G alpha (q) signalling events—PIK3CA—pancreatic cancer	1.58e-05	0.000895	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—DTX4—pancreatic cancer	1.56e-05	0.000886	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—GLI1—pancreatic cancer	1.56e-05	0.000886	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—DTX4—pancreatic cancer	1.56e-05	0.000884	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—GLI1—pancreatic cancer	1.56e-05	0.000884	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—AGTR1—pancreatic cancer	1.55e-05	0.000881	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—AGTR1—pancreatic cancer	1.55e-05	0.000878	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—pancreatic cancer	1.54e-05	0.000874	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—pancreatic cancer	1.54e-05	0.000872	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—CNR1—pancreatic cancer	1.53e-05	0.000868	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—CNR1—pancreatic cancer	1.53e-05	0.000865	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—NRP1—pancreatic cancer	1.52e-05	0.000862	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PPP2R5B—pancreatic cancer	1.52e-05	0.000862	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PPP2R5B—pancreatic cancer	1.52e-05	0.00086	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—NRP1—pancreatic cancer	1.52e-05	0.00086	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GLP1R—pancreatic cancer	1.5e-05	0.000852	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—GCG—pancreatic cancer	1.48e-05	0.000838	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—DPYD—pancreatic cancer	1.48e-05	0.000838	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—GCG—pancreatic cancer	1.47e-05	0.000836	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PRSS1—pancreatic cancer	1.47e-05	0.000834	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—HEY2—pancreatic cancer	1.46e-05	0.00083	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—HEY2—pancreatic cancer	1.46e-05	0.000827	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—TP53—pancreatic cancer	1.45e-05	0.00082	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—GAST—pancreatic cancer	1.43e-05	0.000811	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—GAST—pancreatic cancer	1.43e-05	0.000808	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—pancreatic cancer	1.42e-05	0.000803	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—pancreatic cancer	1.41e-05	0.000801	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—AGTR1—pancreatic cancer	1.41e-05	0.0008	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—AGTR1—pancreatic cancer	1.41e-05	0.000797	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—SLC2A2—pancreatic cancer	1.4e-05	0.000795	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—SCT—pancreatic cancer	1.36e-05	0.000769	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—HEY1—pancreatic cancer	1.36e-05	0.000769	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—SCT—pancreatic cancer	1.35e-05	0.000766	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—HEY1—pancreatic cancer	1.35e-05	0.000766	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	1.31e-05	0.000743	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	1.31e-05	0.000741	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CCK—pancreatic cancer	1.29e-05	0.000733	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CCK—pancreatic cancer	1.29e-05	0.000731	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ARG2—pancreatic cancer	1.28e-05	0.000723	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—GLP1R—pancreatic cancer	1.26e-05	0.000715	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CNR2—pancreatic cancer	1.26e-05	0.000715	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—CXCL8—pancreatic cancer	1.26e-05	0.000714	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CNR2—pancreatic cancer	1.26e-05	0.000712	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—GLP1R—pancreatic cancer	1.26e-05	0.000712	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—CXCL8—pancreatic cancer	1.26e-05	0.000712	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CCKAR—pancreatic cancer	1.24e-05	0.000703	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CCKAR—pancreatic cancer	1.24e-05	0.000701	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—JAG2—pancreatic cancer	1.2e-05	0.000682	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—JAG2—pancreatic cancer	1.2e-05	0.000679	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MEN1—pancreatic cancer	1.19e-05	0.000672	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MEN1—pancreatic cancer	1.18e-05	0.00067	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—PIK3CA—pancreatic cancer	1.16e-05	0.000658	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—SHH—pancreatic cancer	1.13e-05	0.000641	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—SHH—pancreatic cancer	1.13e-05	0.000639	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—NOTCH4—pancreatic cancer	1.12e-05	0.000637	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—NOTCH4—pancreatic cancer	1.12e-05	0.000635	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IAPP—pancreatic cancer	1.12e-05	0.000633	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—TYMP—pancreatic cancer	1.12e-05	0.000632	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IAPP—pancreatic cancer	1.11e-05	0.000631	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CD44—pancreatic cancer	1.09e-05	0.000616	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PTHLH—pancreatic cancer	1.07e-05	0.000608	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PTCH1—pancreatic cancer	1.07e-05	0.000608	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PTHLH—pancreatic cancer	1.07e-05	0.000606	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PTCH1—pancreatic cancer	1.07e-05	0.000606	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GCG—pancreatic cancer	1.04e-05	0.00059	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—SST—pancreatic cancer	9.81e-06	0.000556	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—STK11—pancreatic cancer	9.8e-06	0.000555	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—SST—pancreatic cancer	9.77e-06	0.000554	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—PIK3CG—pancreatic cancer	9.67e-06	0.000548	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—PIK3CG—pancreatic cancer	9.64e-06	0.000546	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PRSS1—pancreatic cancer	9.62e-06	0.000545	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—JAG1—pancreatic cancer	9.6e-06	0.000544	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—JAG1—pancreatic cancer	9.57e-06	0.000542	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—NOTCH3—pancreatic cancer	9.56e-06	0.000542	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—NOTCH3—pancreatic cancer	9.53e-06	0.00054	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—AKT1—pancreatic cancer	9.49e-06	0.000538	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CNR1—pancreatic cancer	9.05e-06	0.000513	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CNR1—pancreatic cancer	9.02e-06	0.000511	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GLP1R—pancreatic cancer	8.99e-06	0.000509	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—DPYD—pancreatic cancer	8.84e-06	0.000501	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PIK3CG—pancreatic cancer	8.78e-06	0.000498	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PIK3CG—pancreatic cancer	8.75e-06	0.000496	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—GCG—pancreatic cancer	8.74e-06	0.000495	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—GCG—pancreatic cancer	8.71e-06	0.000494	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—PIK3CD—pancreatic cancer	8.5e-06	0.000482	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—PIK3CD—pancreatic cancer	8.48e-06	0.00048	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—TYMS—pancreatic cancer	8.43e-06	0.000478	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—SLC2A2—pancreatic cancer	8.39e-06	0.000475	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ARG2—pancreatic cancer	8.34e-06	0.000473	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—AGTR1—pancreatic cancer	8.34e-06	0.000472	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—AGTR1—pancreatic cancer	8.31e-06	0.000471	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—STK11—pancreatic cancer	8.22e-06	0.000466	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—STK11—pancreatic cancer	8.19e-06	0.000464	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PIK3CD—pancreatic cancer	7.72e-06	0.000438	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PIK3CD—pancreatic cancer	7.7e-06	0.000436	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—PIK3CB—pancreatic cancer	7.41e-06	0.00042	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—PIK3CB—pancreatic cancer	7.39e-06	0.000419	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—TYMP—pancreatic cancer	7.29e-06	0.000413	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—SMAD4—pancreatic cancer	7.2e-06	0.000408	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—SMAD4—pancreatic cancer	7.17e-06	0.000407	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—CXCL8—pancreatic cancer	7.12e-06	0.000404	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—CXCL8—pancreatic cancer	7.1e-06	0.000402	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—HES1—pancreatic cancer	7.03e-06	0.000398	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—HES1—pancreatic cancer	7.01e-06	0.000397	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—APOE—pancreatic cancer	6.85e-06	0.000388	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PIK3CB—pancreatic cancer	6.73e-06	0.000381	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PIK3CB—pancreatic cancer	6.71e-06	0.00038	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CD44—pancreatic cancer	6.5e-06	0.000368	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—CXCL8—pancreatic cancer	6.47e-06	0.000366	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—CXCL8—pancreatic cancer	6.45e-06	0.000365	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GCG—pancreatic cancer	6.23e-06	0.000353	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PIK3CG—pancreatic cancer	6.19e-06	0.00035	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TERT—pancreatic cancer	6.16e-06	0.000349	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TERT—pancreatic cancer	6.14e-06	0.000348	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PPARG—pancreatic cancer	5.97e-06	0.000338	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—HIF1A—pancreatic cancer	5.89e-06	0.000334	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GLP1R—pancreatic cancer	5.88e-06	0.000333	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TSC2—pancreatic cancer	5.87e-06	0.000333	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—HIF1A—pancreatic cancer	5.87e-06	0.000333	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—STK11—pancreatic cancer	5.86e-06	0.000332	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TSC2—pancreatic cancer	5.86e-06	0.000332	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—DPYD—pancreatic cancer	5.78e-06	0.000328	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—APOE—pancreatic cancer	5.75e-06	0.000326	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—APOE—pancreatic cancer	5.73e-06	0.000325	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—KDR—pancreatic cancer	5.63e-06	0.000319	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—KDR—pancreatic cancer	5.61e-06	0.000318	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	5.49e-06	0.000311	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PIK3CD—pancreatic cancer	5.44e-06	0.000308	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—NFKBIA—pancreatic cancer	5.36e-06	0.000304	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—NFKBIA—pancreatic cancer	5.34e-06	0.000303	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—NOTCH1—pancreatic cancer	5.31e-06	0.000301	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—NOTCH1—pancreatic cancer	5.29e-06	0.0003	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PIK3CG—pancreatic cancer	5.19e-06	0.000294	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—NRAS—pancreatic cancer	5.19e-06	0.000294	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PIK3CG—pancreatic cancer	5.17e-06	0.000293	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—NRAS—pancreatic cancer	5.17e-06	0.000293	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—EGF—pancreatic cancer	5.13e-06	0.000291	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—EGF—pancreatic cancer	5.11e-06	0.00029	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—TYMS—pancreatic cancer	5.04e-06	0.000286	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PIK3CB—pancreatic cancer	4.74e-06	0.000269	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—EGFR—pancreatic cancer	4.73e-06	0.000268	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—EGFR—pancreatic cancer	4.71e-06	0.000267	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PTGS2—pancreatic cancer	4.7e-06	0.000266	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PIK3CD—pancreatic cancer	4.56e-06	0.000258	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PIK3CD—pancreatic cancer	4.55e-06	0.000258	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—PIK3CA—pancreatic cancer	4.52e-06	0.000256	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—PIK3CA—pancreatic cancer	4.5e-06	0.000255	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—KRAS—pancreatic cancer	4.47e-06	0.000253	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—KRAS—pancreatic cancer	4.45e-06	0.000252	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CD44—pancreatic cancer	4.25e-06	0.000241	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PIK3CA—pancreatic cancer	4.1e-06	0.000232	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—APOE—pancreatic cancer	4.1e-06	0.000232	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PTEN—pancreatic cancer	4.1e-06	0.000232	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PIK3CA—pancreatic cancer	4.09e-06	0.000232	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GCG—pancreatic cancer	4.07e-06	0.000231	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PIK3CB—pancreatic cancer	3.98e-06	0.000225	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PIK3CB—pancreatic cancer	3.96e-06	0.000225	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—STK11—pancreatic cancer	3.83e-06	0.000217	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CXCL8—pancreatic cancer	3.82e-06	0.000216	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CXCL8—pancreatic cancer	3.81e-06	0.000216	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—HRAS—pancreatic cancer	3.8e-06	0.000215	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—HRAS—pancreatic cancer	3.78e-06	0.000214	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	3.7e-06	0.00021	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—AKT1—pancreatic cancer	3.69e-06	0.000209	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—AKT1—pancreatic cancer	3.68e-06	0.000208	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CASP3—pancreatic cancer	3.66e-06	0.000207	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CASP3—pancreatic cancer	3.64e-06	0.000207	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PPARG—pancreatic cancer	3.57e-06	0.000202	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CCND1—pancreatic cancer	3.56e-06	0.000202	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CCND1—pancreatic cancer	3.55e-06	0.000201	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CTNNB1—pancreatic cancer	3.52e-06	0.0002	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CTNNB1—pancreatic cancer	3.51e-06	0.000199	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MMP9—pancreatic cancer	3.46e-06	0.000196	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MMP9—pancreatic cancer	3.44e-06	0.000195	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PTEN—pancreatic cancer	3.44e-06	0.000195	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PTEN—pancreatic cancer	3.42e-06	0.000194	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—AKT1—pancreatic cancer	3.35e-06	0.00019	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—AKT1—pancreatic cancer	3.34e-06	0.000189	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—TYMS—pancreatic cancer	3.29e-06	0.000187	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	3.25e-06	0.000184	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—SRC—pancreatic cancer	3.19e-06	0.000181	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—SRC—pancreatic cancer	3.18e-06	0.00018	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—VEGFA—pancreatic cancer	3.1e-06	0.000176	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—VEGFA—pancreatic cancer	3.09e-06	0.000175	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—STAT3—pancreatic cancer	3.07e-06	0.000174	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—NRAS—pancreatic cancer	3.06e-06	0.000174	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—STAT3—pancreatic cancer	3.06e-06	0.000174	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—NRAS—pancreatic cancer	3.06e-06	0.000173	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PIK3CA—pancreatic cancer	2.89e-06	0.000164	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MYC—pancreatic cancer	2.85e-06	0.000162	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TGFB1—pancreatic cancer	2.85e-06	0.000161	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MYC—pancreatic cancer	2.85e-06	0.000161	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TGFB1—pancreatic cancer	2.84e-06	0.000161	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	2.83e-06	0.000161	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PTGS2—pancreatic cancer	2.81e-06	0.000159	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—EGFR—pancreatic cancer	2.79e-06	0.000158	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—EGFR—pancreatic cancer	2.78e-06	0.000158	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—APOE—pancreatic cancer	2.68e-06	0.000152	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—KRAS—pancreatic cancer	2.64e-06	0.000149	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—KRAS—pancreatic cancer	2.63e-06	0.000149	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PTEN—pancreatic cancer	2.45e-06	0.000139	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PIK3CA—pancreatic cancer	2.42e-06	0.000137	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	2.42e-06	0.000137	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PIK3CA—pancreatic cancer	2.42e-06	0.000137	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—AKT1—pancreatic cancer	2.36e-06	0.000134	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TP53—pancreatic cancer	2.34e-06	0.000133	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TP53—pancreatic cancer	2.34e-06	0.000132	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PPARG—pancreatic cancer	2.33e-06	0.000132	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—HRAS—pancreatic cancer	2.24e-06	0.000127	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—HRAS—pancreatic cancer	2.24e-06	0.000127	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	2.13e-06	0.00012	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—AKT1—pancreatic cancer	1.98e-06	0.000112	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—AKT1—pancreatic cancer	1.97e-06	0.000112	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	1.85e-06	0.000105	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PTGS2—pancreatic cancer	1.84e-06	0.000104	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	1.73e-06	9.79e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PTEN—pancreatic cancer	1.6e-06	9.07e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—AKT1—pancreatic cancer	1.41e-06	8e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.13e-06	6.4e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—AKT1—pancreatic cancer	9.23e-07	5.23e-05	CbGpPWpGaD
